U.S. insulin manufacturer and pharmacy benefit manager (PBM) business practices “have created a vicious cycle of price increases that have sent costs for patients and taxpayers through the roof,” U.S. Senate Finance Committee leaders Chuck Grassley (R-Iowa) and Ron Wyden
…Category: Legislative
The incoming Democratic chairs of two key U.S. Senate committees want the federal agency in charge of the 340B program “to take immediate action to clarify that implementation of a rebate model by [drug] manufacturers would violate a material condition
…Iowa’s U.S. Senators Meet With HHS Top Brass About Pharma’s 340B Moves
Both of Iowa’s U.S. senators met yesterday with “top officials” at the U.S. Health and
…U.S. House Democrats and Republicans “Deeply Concerned” About 340B Rebate Model
Update, Thursday Oct. 22, 2020, 2:45 p.m. EDT—Kalderos provided us with the following updated comment regarding members of Congress’ concerns about its 340B Pay platform to enable drug manufacturers
…Congressional GOP Committee Leaders Seek 340B Reform Ideas by Oct. 30
The Republican chairman of the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee and the
…A message from 340B Report Publisher and CEO Ted Slafsky: We are pleased to have a sponsored content article today from Michael Gonzalez, President and Lead Consultant, FQHC340B, a valued 340B Report sponsor. I encourage you to read it. We will
…